Spanish privately-held pharma company entered into an agreement to acquire USA-based TerSera's Infusion Specialty Therapies ...

Sarepta Therapeutics, Inc. reported FY25 revenue of $1.86B, maintains a robust cash position of $953.8M. Click here to read ...

As we get older, pain quietly becomes a background feature of life. Aches after the weekend. Stiffness in the morning. A ...

The FDA has relaxed a clinical hold on clinical trials of Novartis' intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new phase 3 trial to get underway.

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

Discover a comprehensive palliative care plan designed to enhance quality of life for those with metastatic bladder cancer.

The study introduces a novel "multi-route" administration protocol for Wharton’s Jelly-derived Mesenchymal Stem Cells (WJ-MSCs). Unlike previous trials that relied on a single delivery method, this ...

aDepartment of Neurology, Thomas Jefferson University Medical College, Philadelphia, PA, USA, bSection of Neurology, Christiana Care Health Systems, Wilmington, DE, USA, cDepartment of Neurology and ...